Author Archives: David Melamed, PhD

The Israeli Innovation Authority has awarded Owlytics Healthcare a $1.3-million grant to support the company’s development of wearable artificial intelligence (AI) technology that has the potential to improve multiple sclerosis (MS) therapies and better evaluate treatment efficacy in clinical studies. The device would be able to continuously…

Patients with multiple sclerosis (MS) report moderate scores in mental and physical health, as measured by three, well-established quality-of-life scales, according to an analysis of published literature. The study, “Global, regional and national quality of life in patients with multiple sclerosis: a global systematic review and…

The Multiple Sclerosis Association of America (MSAA) teamed with Wondros, a creative production company, to launch COVID-19 and MS Pathfinder, an online platform offering the multiple sclerosis (MS) community accurate and regularly updated information to help in safely navigating the COVID-19 pandemic. Topics covered range from managing MS symptoms…

Young men, ages 16 to 20, with a higher the body mass index (BMI) are at greater their risk of being diagnosed with multiple sclerosis (MS) later in life, regardless of physical fitness, according to a Swedish study. Risk rose across “the entire BMI range,” its researchers reported,…

The University of Alberta and PROTXX are collaborating to develop wearable sensors for people with multiple sclerosis (MS) and advance a remote healthcare platform that facilitates personalized care and reduces frequency of hospital visits. The wearable sensors will help monitor neurological, sensory, and musculoskeletal symptoms without the need to…

MyHealthTeams and EMD Serono have teamed up to launch the Treatment and Adherence Resource Center, a new informational tool within the MyMSTeam social network for people living with multiple sclerosis (MS). The new resource center is geared toward educating MS patients about the importance of starting…

People with multiple sclerosis (MS) exert increased caution with their walking pattern and take smaller steps overall, a study shows. These findings could contribute to the development of better walking rehabilitation programs and decrease the risk of falls. The study, “Influence of Multiple Sclerosis on Dynamic…

Andrographolide, an herbal compound with anti-inflammatory and neuroprotective properties, is able to slow brain atrophy and progression of disability in people with non-active progressive multiple sclerosis (PMS), according to results from a Phase 1/2 clinical trial. The study, “Efficacy of andrographolide in not active progressive…

Researchers at Vrije University Amsterdam in the Netherlands are inviting employed people with multiple sclerosis (MS) to take part in an online survey, in the form of three questionnaires spaced over two months, on their working life. This study will investigating potential connections between the perceived severity of MS symptoms, and…

A study from Spain found the diet of multiple sclerosis (MS) patients to contain more fat and protein, and fewer carbohydrates, than recommended, which was linked to abdominal weight gain and higher levels of inflammation. As “an excessive intake of lipids” is known to be “related to oxidative stress…

A planned Phase 2 clinical trial of a potential treatment for progressive multiple sclerosis has been postponed to keep hospital resources open to treat people with COVID-19 during the ongoing global outbreak, and to reduce the risk of exposure to MS patients, GeNeuro, the investigate therapy’s developer, announced. The…

About 85% of people with multiple sclerosis (MS) using cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis,” was published in…

A new test involving a virtual reality simulation was able to detect balance issues in patients with multiple sclerosis (MS), potentially allowing doctors to identify whether a patient is at risk of falling despite having no apparent problems with walking, according to new research. The results of the study,…

Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found. The results were published in an article, “Effect of…